Latest Articles
Trastuzumab Pamirtecan Elicits Responses in HER2-Expressing Advanced/Metastatic Endometrial Cancer - OncLive
Trastuzumab Pamirtecan Elicits Responses in HER2-Expressing Advanced/Metastatic Endometrial Cancer OncLive
Published: April 11, 2026, 6:14 p.m.
St. Louis Cardinals Rally, Dustin May DELIVERS Stellar Outing Against Boston! - newscentermaine.com
St. Louis Cardinals Rally, Dustin May DELIVERS Stellar Outing Against Boston! newscentermaine.com
Published: April 11, 2026, 6:12 p.m.
Black Maternal Health Week shines light on disparities Black women face on path to motherhood - ABC7 Chicago
Black Maternal Health Week shines light on disparities Black women face on path to motherhood ABC7 Chicago
Published: April 11, 2026, 4:29 p.m.
Abemaciclib Plus Letrozole Displays Durable Activity in Advanced/Recurrent Endometrioid Endometrial Carcinoma - OncLive
Abemaciclib Plus Letrozole Displays Durable Activity in Advanced/Recurrent Endometrioid Endometrial Carcinoma OncLive
Published: April 11, 2026, 4:04 p.m.
Your Guide to IVF, Courtesy of Lo Bosworth's Doctor - dearmedia.com
Your Guide to IVF, Courtesy of Lo Bosworth's Doctor dearmedia.com
Published: April 11, 2026, 2:47 p.m.
BioNTech's Trastuzumab Pamirtecan Achieves Positive Phase 2 Results in Advanced HER2-Expressing Endometrial Cancer - Quiver Quantitative
BioNTech's Trastuzumab Pamirtecan Achieves Positive Phase 2 Results in Advanced HER2-Expressing Endometrial Cancer Quiver Quantitative
Published: April 11, 2026, 11:10 a.m.
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer - The Manila Times
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer The Manila Times
Published: April 11, 2026, 11:01 a.m.
In recurrent endometrial cancer, BioNTech drug held off progression 8 months - Stock Titan
In recurrent endometrial cancer, BioNTech drug held off progression 8 months Stock Titan
Published: April 11, 2026, 11 a.m.
Progesterone in MHT for Protection Against Endometrial Cancer - The Vajenda
Progesterone in MHT for Protection Against Endometrial Cancer The Vajenda
Published: April 11, 2026, 9:17 a.m.
Australia's Cartherics expands agreement with Catalent to focus on cancer and endometriosis treatment - BioSpectrum Asia
Australia's Cartherics expands agreement with Catalent to focus on cancer and endometriosis treatment BioSpectrum Asia
Published: April 11, 2026, 7:52 a.m.
Link copied to clipboard!